about
Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques.Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice.Social media and pharmacovigilance: A review of the opportunities and challenges.Opioid and chronic non-cancer painA Survey of Spinal Cord Stimulator Use by Chronic Pain Patients While Driving.The meaning of resilience to persons living with chronic pain: an interpretive qualitative inquiry.Chronic pain and the family: the experience of the partners of people living with chronic pain.Dealing with chronic pain: giving voice to the experiences of mothers with chronic pain and their children.Medical cannabis and chronic opioid therapy.Utility of saccadic eye movement analysis as an objective biomarker to detect the sedative interaction between opioids and sleep deprivation in opioid-naive and opioid-tolerant populations.Stable long-term opioid medication per se does not always cause loss of driving ability: the doctor and patient must consider additional risk factors for unsafe driving.European Pain Federation position paper on appropriate opioid use in chronic pain management.Interactions between metoclopramide and morphine: enhanced antinociception and motor dysfunction in rats.Scientific Opinion on the risks for public health related to the presence of opium alkaloids in poppy seedsEuropean Pain Management Discussion Forum
P2860
Q30248258-C664C50A-9ECD-4E53-9685-EF3E6D572119Q33938745-C3A14D4B-D309-445F-8AD1-68D034CC3E33Q35124200-F9D5B65B-FB1F-4376-8BCC-C7B4DE046BFCQ36109980-B14EC14F-5EB2-4C8F-B4D9-5FF46E1ADD3AQ36125558-0033C42F-407B-4DD9-8598-4A56D4BAEE73Q36663226-41517ADE-0496-4F50-933B-15D4BCA0F4EDQ39180898-438F8A60-0BD0-4EC7-9A82-7C69DBB62A36Q39292544-45F4B0E4-828E-4361-BF49-F91C6D72DE77Q39579367-ECBAC232-DD89-4B8A-9CCE-5D92506C1BB9Q42648806-82455485-DB30-49FB-BAE5-545B786F8C91Q42785502-6E93363F-9D0C-41F3-91C5-1BC40D8E767DQ43168350-5E0F8ABD-0B7C-4558-8FD4-4D732CD6AD2EQ44332090-885DA3B2-269F-4268-AE06-C5FB5D84D656Q44342097-B4EB588A-919C-4812-933E-8E83BF179C34Q46538262-8B2EE362-689F-4D4B-BF94-1B62911AFFB7Q47150721-C65D01D7-FC4C-4605-A8BE-C8F8FAC5F07AQ57878385-708A883F-E145-4669-A914-1881D87A34A8
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Opioid medication and driving ability.
@ast
Opioid medication and driving ability.
@en
type
label
Opioid medication and driving ability.
@ast
Opioid medication and driving ability.
@en
prefLabel
Opioid medication and driving ability.
@ast
Opioid medication and driving ability.
@en
P2860
P1476
Opioid medication and driving ability
@en
P2093
Hans G Kress
P2860
P304
P356
10.1016/J.EJPAIN.2004.05.010
P50
P577
2005-04-01T00:00:00Z